Vancomycin-resistente Enterokokken: Erhöhte Sterblichkeit durch Tigecyclin?

Zum Beitrag „Vancomycin-resistente Enterokokken: Welche Therapieoptionen gibt es?“ DMW 1 / 201510.1055/s-0041-102303

Abkürzungen

cIAI: : complicated intra-abdominal infections

cSSTI: : complicated skin and soft tissue infection

CAP: : community-acquired pneumonia

• Literatur

• 1 Mutters NT, Werner G, Tacconelli E, Mischnik A. Vancomycin-resistente Enterokokken: Welche Therapieoptionen gibt es?. Dtsch med Wochenschr 2015; 140: 42-45
• 2 FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections?. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm
• 3 Girou E, Stephan F, Novara A et al. Risk Factors and Outcome of Nosocomial Infections: Results of a Matched Case-control Study of ICU Patients. Am J Respir Crit Care Med 1998; 157: 1151-1158
• 4 Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996; 17: 552-557
• 5 Rocker G, Cook D, Sjokvist P et al. Level of Care Study Investigators; Canadian Critical Care Trials Group. Clinician predictions of intensive care unit mortality. Crit Care Med 2004; 32: 1149-1154
• 6 Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical data. Clin Infect Dis 2005; 41: 354-366
• 7 Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections; results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 (Suppl. 05) S341-S353
• 8 Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-338
• 9 Brun-Buisson C, Sollet JP, Schweich H et al. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam / amikacin vs ceftazidime / amikacin: a multicenter, randomized controlled trial. Clin Infect Dis 1998; 26: 346-354
• 10 Jaccard C, Troillet N, Harbarth S et al. Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-2972